Inventor · disambiguated record
Joanne M. Smallheer
Also filed as: SMALLHEER JOANNE · SMALLHEER JOANNE M · SMALLHEER JOANNE MARIE
38 granted patents·439 citations·filing 1988–2021
97Inventor score
Files withBRISTOL MYERS SQUIBB CO23BRISTOL MYERS SQUIBB PHARMA CO3DU PONT MERCK PHARMA3SMITHKLINE BEECHAM CORP3HANGELAND JON J2
Top patents by PatentIndex Score
38 records- 0197US7459564B2Substituted biaryl compounds as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Dec 2, 2008·26 cites·14 claims
- 0294US7453002B2Five-membered heterocycles useful as serine protease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Nov 18, 2008·24 cites·17 claims
- 0394US7129264B2Biarylmethyl indolines and indoles as antithromboembolic agentsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 31, 2006·88 cites·30 claims
- 0493US7417063B2Bicyclic heterocycles useful as serine protease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 26, 2008·27 cites·14 claims
- 0593US5760029ASpirocycle integrin inhibitorsDU PONT MERCK PHARMA·Filed 1997·Granted Jun 2, 1998·73 cites·7 claims
- 0691US10487086B2Macrocycles as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Nov 26, 2019·3 cites·9 claims
- 0791US8940720B2Macrocycles as factor XIa inhibitorsCORTE JAMES R·Filed 2011·Granted Jan 27, 2015·6 cites·4 claims
- 0891US7626039B2Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Dec 1, 2009·14 cites·14 claims
- 0991US7429604B2Six-membered heterocycles useful as serine protease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Sep 30, 2008·35 cites·20 claims
- 1091US6710058B2Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Mar 23, 2004·28 cites·23 claims
- 1190US7645799B2Substituted biaryl compounds as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Jan 12, 2010·7 cites·16 claims
- 1289US9802939B2Macrocycles as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Oct 31, 2017·3 cites·9 claims
- 1386US11136327B2Macrocycles as factor XIA inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 5, 2021·1 cites·11 claims
- 1485US7157470B2Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jan 2, 2007·24 cites·24 claims
- 1585US5710159AIntegrin receptor antagonistsDU PONT MERCK PHARMA·Filed 1996·Granted Jan 20, 1998·39 cites·21 claims
- 1684US6951872B2Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2003·Granted Oct 4, 2005·14 cites·21 claims
- 1783US7842708B2Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Nov 30, 2010·4 cites·16 claims
- 1882US8101778B2Five-membered heterocycles useful as serine protease inhibitorsHANGELAND JON J·Filed 2008·Granted Jan 24, 2012·5 cites·2 claims
- 1980US12404274B2Macrocycles as factor xia inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Sep 2, 2025·0 cites·8 claims
- 2075US10214527B2Triazolopyridine inhibitors of myeloperoxidaseBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Feb 26, 2019·2 cites·9 claims
- 2175US8716492B2Five-membered heterocycles useful as serine protease inhibitorsHANGELAND JON J·Filed 2011·Granted May 6, 2014·2 cites·10 claims
- 2272US7524863B2Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Apr 28, 2009·1 cites·14 claims
- 2366US10407422B2Triazolopyridine inhibitors of myeloperoxidaseBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 10, 2019·1 cites·11 claims
- 2465US9079860B2Five-membered heterocycles useful as serine protease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jul 14, 2015·0 cites·4 claims
- 2561US10112936B2Five-membered heterocycles useful as serine protease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 30, 2018·0 cites·2 claims
- 2659US6476226B2Isoxazoline fibrinogen receptor antagonistsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Nov 5, 2002·1 cites·13 claims
- 2758US8604056B2Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitorsPINTO DONALD J P·Filed 2012·Granted Dec 10, 2013·0 cites·5 claims
- 2856US9617224B2Five-membered heterocycles useful as serine protease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 11, 2017·0 cites·10 claims
- 2953US8252830B2Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitorsPINTO DONALD J P·Filed 2010·Granted Aug 28, 2012·0 cites·4 claims
- 3049US4937253AEster prodrugsSMITHKLINE BEECHAM CORP·Filed 1988·Granted Jun 26, 1990·6 cites·26 claims
- 3148US11180490B2Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 23, 2021·0 cites·12 claims
- 3247US5543517ASubstituted bicyclic phosphoramides and derivatives thereofDU PONT MERCK PHARMA·Filed 1994·Granted Aug 6, 1996·4 cites·4 claims
- 3339US11059818B2Triazolopyridine inhibitors of myeloperoxidaseBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jul 13, 2021·0 cites·5 claims
- 3438US11008317B2Triazolopyridine inhibitors of myeloperoxidase and/or EPXBRISTOL MYERS SQUIBB CO·Filed 2017·Granted May 18, 2021·0 cites·5 claims
- 3538US10577383B2Macrocyclic inhibitors of myeloperoxidaseBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 3, 2020·0 cites·5 claims
- 3636US4954513ALeukotriene antagonistsSMITHKLINE BEECHAM CORP·Filed 1988·Granted Sep 4, 1990·1 cites·14 claims
- 3733US6303609B1Isoxazoline fibrinogen receptor antagonistsDU PONT PHARM CO·Filed 1999·Granted Oct 16, 2001·0 cites·55 claims
- 3828US5189226AOrtho-substituted benzaldehydesSMITHKLINE BEECHAM CORP·Filed 1990·Granted Feb 23, 1993·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Joanne M. Smallheer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →